Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Avidity Biosciences Corp a un objectif de cours consensuel de 567,61 $ basé sur les notes de 38 analystes. Le plus haut est de 1 350 $ émis par HSBC le 10 mai 2024<. Le plus bas est de 100 $ émis par Deutsche Bank le 5 août 2024. Les 3 dernières notations d'analystes ont été publiées par New Street Research, Goldman Sachs et Deutsche Bank respectivement le 6 août 2024, le 5 août 2024 et le 5 août 2024. Avec un objectif de cours moyen de 118,33 $ entre New Street Research, Goldman Sachs et Deutsche Bank, il existe une hausse implicite de 0,21 % pour Avidity Biosciences Corp à partir de ces notations d'analystes les plus récentes.
Sociétés d'analyse émettant des recommandations1
TD Cowen
Chardan Capital
RBC Capital
Citigroup
Leerink Partners
1calculé à partir des notes des analystes
Notes d'analystes pour Avidity Biosciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
10/29/2025 | — | TD Cowen | $78 → $74 | Downgrade | Buy → Hold | |||
10/28/2025 | — | Chardan Capital | $75 → $72 | Downgrade | Buy → Neutral | |||
10/28/2025 | — | RBC Capital | $61 → $72 | Downgrade | Outperform → Sector Perform | |||
10/27/2025 | — | Citigroup | $75 → $72 | Downgrade | Buy → Neutral | |||
10/27/2025 | — | Leerink Partners | $65 → $72 | Downgrade | Outperform → Market Perform | |||
10/27/2025 | — | Raymond James | — | Downgrade | Strong Buy → Market Perform | |||
10/27/2025 | — | Bernstein | $52 → $72 | Downgrade | Outperform → Market Perform | |||
10/27/2025 | — | Needham | $65 → $65 | Downgrade | Buy → Hold | |||
10/27/2025 | — | HC Wainwright & Co. | $87 → $72 | Downgrade | Buy → Neutral | |||
09/22/2025 | — | Evercore ISI Group | $70 → $65 | Maintains | Outperform | |||
09/17/2025 | — | Roth Capital | → $62 | Initiates | → Buy | |||
09/15/2025 | — | B of A Securities | $56 → $65 | Maintains | Buy | |||
09/12/2025 | — | HC Wainwright & Co. | $68 → $87 | Maintains | Buy | |||
09/10/2025 | — | Needham | $60 → $65 | Maintains | Buy | |||
09/10/2025 | — | Chardan Capital | $75 → $75 | Maintains | Buy | |||
08/08/2025 | — | Wells Fargo | $70 → $75 | Maintains | Overweight | |||
08/08/2025 | — | Barclays | $59 → $62 | Maintains | Overweight | |||
08/08/2025 | — | Chardan Capital | $75 → $75 | Maintains | Buy | |||
07/10/2025 | — | Goldman Sachs | → $55 | Reinstates | → Buy | |||
06/27/2025 | — | Cantor Fitzgerald | $96 → $96 | Reiterates | Overweight → Overweight | |||
06/17/2025 | — | Wolfe Research | → $55 | Initiates | → Outperform | |||
06/11/2025 | — | Raymond James | → $65 | Initiates | → Strong Buy | |||
06/10/2025 | — | Citigroup | $70 → $75 | Maintains | Buy | |||
06/10/2025 | — | Barclays | $57 → $59 | Maintains | Overweight | |||
06/09/2025 | — | B of A Securities | $48 → $54 | Maintains | Buy | |||
06/09/2025 | — | Chardan Capital | $65 → $75 | Maintains | Buy | |||
05/12/2025 | — | HC Wainwright & Co. | $72 → $68 | Maintains | Buy | |||
05/09/2025 | — | Chardan Capital | $65 → $65 | Maintains | Buy | |||
05/07/2025 | — | Chardan Capital | $65 → $65 | Maintains | Buy | |||
04/09/2025 | — | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
03/18/2025 | — | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
03/17/2025 | — | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
03/17/2025 | — | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
03/17/2025 | — | Chardan Capital | $65 → $65 | Maintains | Buy | |||
03/13/2025 | — | Citigroup | → $70 | Initiates | → Buy | |||
03/12/2025 | — | BMO Capital | → $72 | Initiates | → Outperform | |||
03/10/2025 | — | B of A Securities | $51 → $48 | Maintains | Buy | |||
03/07/2025 | — | Scotiabank | → $70 | Initiates | → Sector Outperform | |||
02/28/2025 | — | Barclays | $63 → $57 | Maintains | Overweight | |||
02/28/2025 | — | Chardan Capital | $65 → $65 | Maintains | Buy | |||
01/21/2025 | — | RBC Capital | $67 → $67 | Reiterates | Outperform → Outperform | |||
01/10/2025 | — | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
12/20/2024 | — | HC Wainwright & Co. | → $72 | Initiates | → Buy | |||
11/26/2024 | — | RBC Capital | → $67 | Initiates | → Outperform | |||
11/13/2024 | — | Chardan Capital | $65 → $65 | Maintains | Buy | |||
11/13/2024 | — | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
10/31/2024 | — | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
10/30/2024 | — | Chardan Capital | $60 → $65 | Maintains | Buy | |||
10/21/2024 | — | TD Cowen | $56 → $78 | Maintains | Buy | |||
09/24/2024 | — | Goldman Sachs | → $59 | Initiates | → Buy | |||
09/18/2024 | — | Cantor Fitzgerald | $96 → $96 | Reiterates | Overweight → Overweight | |||
09/16/2024 | — | Cantor Fitzgerald | $96 → $96 | Reiterates | Overweight → Overweight | |||
09/09/2024 | — | Cantor Fitzgerald | $96 → $96 | Reiterates | Overweight → Overweight | |||
08/28/2024 | — | Barclays | → $63 | Initiates | → Overweight | |||
08/26/2024 | — | Evercore ISI Group | $54 → $53 | Maintains | Outperform | |||
08/13/2024 | — | Needham | $60 → $60 | Reiterates | Buy → Buy | |||
08/12/2024 | — | Evercore ISI Group | $45 → $54 | Maintains | Outperform | |||
08/09/2024 | — | Chardan Capital | $45 → $60 | Maintains | Buy | |||
06/13/2024 | — | B of A Securities | $40 → $45 | Maintains | Buy | |||
06/12/2024 | — | Needham | $35 → $46 | Maintains | Buy | |||
06/12/2024 | — | Chardan Capital | $33 → $45 | Maintains | Buy | |||
06/12/2024 | — | Evercore ISI Group | $40 → $45 | Maintains | Outperform | |||
06/10/2024 | — | Needham | $35 → $35 | Reiterates | Buy → Buy | |||
05/10/2024 | — | Needham | $35 → $35 | Reiterates | Buy → Buy | |||
05/10/2024 | — | Chardan Capital | $33 → $33 | Maintains | Buy | |||
05/03/2024 | — | B of A Securities | → $40 | Initiates | → Buy | |||
04/11/2024 | — | Needham | $35 → $35 | Reiterates | Buy → Buy | |||
03/14/2024 | — | Cantor Fitzgerald | → $60 | Initiates | → Overweight | |||
03/05/2024 | — | Chardan Capital | $23 → $33 | Maintains | Buy | |||
03/04/2024 | — | Needham | $35 → $35 | Reiterates | Buy → Buy | |||
02/29/2024 | — | Needham | $35 → $35 | Reiterates | Buy → Buy | |||
02/29/2024 | — | Chardan Capital | → $23 | Reiterates | Buy → Buy | |||
01/03/2024 | — | Wells Fargo | $50 → $50 | Reiterates | Overweight → Overweight | |||
11/29/2023 | — | Needham | → $35 | Reiterates | Buy → Buy | |||
08/09/2023 | — | Credit Suisse | → $30 | Reiterates | Outperform → Outperform | |||
08/09/2023 | — | Chardan Capital | $27 → $23 | Maintains | Buy | |||
08/09/2023 | — | Needham | → $35 | Reiterates | Buy → Buy | |||
05/22/2023 | — | Evercore ISI Group | → $20 | Upgrade | In-Line → Outperform | |||
05/17/2023 | — | Needham | → $35 | Reiterates | Buy → Buy | |||
05/11/2023 | — | Wells Fargo | $55 → $50 | Maintains | Overweight | |||
05/10/2023 | — | Credit Suisse | → $30 | Reiterates | → Outperform | |||
04/28/2023 | — | Needham | → $35 | Reiterates | → Buy | |||
03/31/2023 | — | Credit Suisse | $35 → $30 | Maintains | Outperform | |||
03/31/2023 | — | Evercore ISI Group | → $20 | Downgrade | Outperform → In-Line | |||
03/31/2023 | — | Chardan Capital | → $27 | Reiterates | → Buy | |||
03/01/2023 | — | Credit Suisse | → $35 | Reiterates | → Outperform | |||
03/01/2023 | — | Chardan Capital | → $27 | Reiterates | → Buy | |||
03/01/2023 | — | Needham | → $35 | Reiterates | → Buy | |||
01/04/2023 | — | Wells Fargo | $60 → $55 | Maintains | Overweight | |||
12/15/2022 | — | Credit Suisse | $33 → $35 | Maintains | Outperform | |||
12/15/2022 | — | Raymond James | $30 → $71 | Maintains | Strong Buy | |||
12/14/2022 | — | Raymond James | $30 → $71 | Maintains | Strong Buy | |||
11/09/2022 | — | Credit Suisse | $32 → $33 | Maintains | Outperform | |||
11/09/2022 | — | Raymond James | $29 → $30 | Maintains | Strong Buy |
FAQ
Quel est le cours indicatif de l'action Avidity Biosciences (RNA) ?
Le dernier objectif de prix pour Avidity Biosciences (NASDAQ:RNA) a été rapporté par TD Cowen le octobre 29, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $74.00 s'attendant à ce que RNA se rise dans les 12 prochains mois (un possible changement de 5.88% upside). 48 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Avidity Biosciences (RNA) ?
La dernière note d'analyste pour Avidity Biosciences (NASDAQ:RNA) a été fournie par TD Cowen, et Avidity Biosciences réduit leur note hold.
Quand a eu lieu la dernière mise à niveau pour Avidity Biosciences (RNA) ?
La dernière amélioration pour Avidity Biosciences Inc a eu lieu le mai 22, 2023 lorsque Evercore ISI Group a augmenté leur objectif de prix à $20. Evercore ISI Group avait précédemment an in-line pour Avidity Biosciences Inc.
Quand a eu lieu la dernière dégradation pour Avidity Biosciences (RNA) ?
La dernière réduction pour Avidity Biosciences Inc a eu lieu le octobre 29, 2025 lorsque TD Cowen a changé leur objectif de prix de $78 à $74 pour Avidity Biosciences Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Avidity Biosciences (RNA) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Avidity Biosciences, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Avidity Biosciences a été déposée le octobre 29, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers octobre 29, 2026.
La note d'analyste pour Avidity Biosciences (RNA) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Avidity Biosciences (RNA) était un réduit avec un objectif de prix de $78.00 à $74.00. Le prix actuel de Avidity Biosciences (RNA) est de $69.89, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.